IL321468A - Compositions for inhibition of kras expression and methods of use thereof - Google Patents

Compositions for inhibition of kras expression and methods of use thereof

Info

Publication number
IL321468A
IL321468A IL321468A IL32146825A IL321468A IL 321468 A IL321468 A IL 321468A IL 321468 A IL321468 A IL 321468A IL 32146825 A IL32146825 A IL 32146825A IL 321468 A IL321468 A IL 321468A
Authority
IL
Israel
Prior art keywords
kras
methods
mutations
compounds
cancer
Prior art date
Application number
IL321468A
Other languages
English (en)
Hebrew (he)
Inventor
Shirvan Mitchell
MALKA GABAI Rachel
YARON Michal
POLLACK-SHRAGAI Orit
Original Assignee
Silexion Therapeutics Ltd
Shirvan Mitchell
MALKA GABAI Rachel
YARON Michal
Orit Pollack Shragai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silexion Therapeutics Ltd, Shirvan Mitchell, MALKA GABAI Rachel, YARON Michal, Orit Pollack Shragai filed Critical Silexion Therapeutics Ltd
Publication of IL321468A publication Critical patent/IL321468A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL321468A 2022-12-15 2023-12-14 Compositions for inhibition of kras expression and methods of use thereof IL321468A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263387504P 2022-12-15 2022-12-15
US202363491776P 2023-03-23 2023-03-23
PCT/IL2023/051276 WO2024127405A2 (en) 2022-12-15 2023-12-14 Compositions for inihibition of kras expression and methods of use thereof

Publications (1)

Publication Number Publication Date
IL321468A true IL321468A (en) 2025-08-01

Family

ID=91485359

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321468A IL321468A (en) 2022-12-15 2023-12-14 Compositions for inhibition of kras expression and methods of use thereof

Country Status (7)

Country Link
EP (1) EP4634387A2 (de)
JP (1) JP2025541376A (de)
KR (1) KR20250148564A (de)
CN (1) CN120712351A (de)
AU (1) AU2023393488A1 (de)
IL (1) IL321468A (de)
WO (1) WO2024127405A2 (de)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889642B2 (en) * 2012-04-19 2014-11-18 Silenseed Ltd. Methods and compositions for RNAi-based cancer treatment

Also Published As

Publication number Publication date
KR20250148564A (ko) 2025-10-14
JP2025541376A (ja) 2025-12-18
WO2024127405A2 (en) 2024-06-20
EP4634387A2 (de) 2025-10-22
AU2023393488A1 (en) 2025-07-24
WO2024127405A3 (en) 2024-07-25
CN120712351A (zh) 2025-09-26

Similar Documents

Publication Publication Date Title
Sun et al. Resveratrol inhibits the progression of cervical cancer by suppressing the transcription and expression of HPV E6 and E7 genes
Huang et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1
Cao et al. The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING
Qie et al. Cyclin D1, cancer progression, and opportunities in cancer treatment
Dhall et al. Sumoylated human histone H4 prevents chromatin compaction by inhibiting long-range internucleosomal interactions
Lu et al. The ETS transcription factor ETV6 constrains the transcriptional activity of EWS–FLI to promote Ewing sarcoma
Deep et al. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells
Feng et al. DNA 5mC and RNA m6A modification successively facilitates the initiation and perpetuation stages of HSC activation in liver fibrosis progression
Yu et al. A complex between DYRK1A and DCAF7 phosphorylates the C-terminal domain of RNA polymerase II to promote myogenesis
Liu et al. Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress
Yuan et al. α-CaMKII controls the growth of human osteosarcoma by regulating cell cycle progression
Jung et al. Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma
Kehn et al. Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells
Rai et al. Transcriptomic analysis identifies differentially expressed genes associated with vascular cuffing and chronic inflammation mediating early thrombosis in arteriovenous fistula
Dong et al. Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma
Nallar et al. Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis
Kim et al. Oncogenic IL7R is downregulated by histone deacetylase inhibitor in esophageal squamous cell carcinoma via modulation of acetylated FOXO1
Zalcman et al. Androgen receptor activation in glioblastoma can Be achieved by ligand-independent signaling through EGFR—a potential therapeutic target
Li et al. Discovery of the natural product 3', 4', 7, 8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor
Feng et al. NEDD4L represses prostate cancer cell proliferation via modulating PHF8 through the ubiquitin–proteasome pathway
Jeong et al. Novel role of Pin1 induction in type II collagen-mediated rheumatoid arthritis
Li et al. Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma
Lumahan et al. Regulating androgen receptor function in prostate cancer: exploring the diversity of post-translational modifications
Kandeel et al. Design, synthesis, and cytotoxicity evaluation of novel indolin-2-one based molecules on hepatocellular carcinoma HepG2 cells as protein kinase inhibitors
Czegle et al. The role of genetic mutations in mitochondrial-driven cancer growth in selected tumors: breast and gynecological Malignancies